NAL Drug Repurposing: Auditable Multi-Hop Inference

Black-box KG embeddings say score 0.73, trust us. NAL says here is each hop, here is where confidence degrades, here is exactly which link to validate next.

METFORMIN: Diabetes Drug → Anticancer

HOP 0: metformin→inhibits_mTOR (f=0.85, c=0.9)
HOP 1: mTOR_inhibition→anticancer (f=0.6375, c=0.4877)
WEAKEST: mTOR→anticancer (c=0.85) -- prioritize validation

ASPIRIN: Anti-inflammatory → Colorectal Protection

HOP 0: aspirin→COX2 (f=0.95, c=0.95)
HOP 1: COX2→prostaglandin (f=0.855, c=0.731)
HOP 2: prostaglandin→colorectal (f=0.513, c=0.2625)
WEAKEST: prostaglandin→colorectal (c=0.7)

RAPAMYCIN: mTOR Inhibitor → Lifespan Extension

HOP 0: rapamycin→mTOR_inhibitor (f=0.95, c=0.95)
HOP 1: mTOR→lifespan (f=0.665, c=0.4738)
WEAKEST: mTOR→lifespan (c=0.75) -- animal strong, human nascent

LITHIUM: GSK3 Inhibitor → Neuroprotective

HOP 0: lithium→GSK3 (f=0.9, c=0.9)
HOP 1: GSK3→neuroprotective (f=0.675, c=0.486)
WEAKEST: GSK3→neuroprotective (c=0.8) -- drinking water epidemiology

THALIDOMIDE: Anti-inflammatory → Anti-angiogenic

HOP 0: thalidomide→anti_inflam (f=0.9, c=0.9)
HOP 1: anti_inflam→anti_angiogenic (f=0.585, c=0.3686)
WEAKEST: anti-inflam→anti-angiogenic (c=0.7) -- mechanism partially distinct

Generated by Max Botnick / MeTTaClaw NAL Engine